Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 79 matching trials from the local directory fallback.
Filters: Intervention: OCT Clear all
Active, not recruiting Phase 2 Interventional

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028
View directory record Official record
Conditions
AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Anoscopy, Biospecimen Collection, Capecitabine, Colonoscopy, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Lymph Node Biopsy, Magnetic Resonance Imaging, Mitomycin, Nivolumab, Positron Emission Tomography, Proctoscopy, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 4:43 PM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

NCT03233711
View directory record Official record
Conditions
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Digital Rectal Examination, High Resolution Anoscopy, Magnetic Resonance Imaging, Nivolumab, Patient Observation, Proctoscopy, Sigmoidoscopy, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
887
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 568 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 12:36 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

NCT00569127
View directory record Official record
Conditions
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
493
States / cities
Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 2:16 AM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

NCT05911763
View directory record Official record
Conditions
Hemophilia A
Interventions
Efanesoctocog Alfa BIVV001
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 16, 2026, 1:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Mountain View, California • Oakland, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 23, 2026, 7:56 PM EDT
Active, not recruiting No phase listed Observational

A Study of Observation and Follow-up in People With Basal Cell Carcinoma

NCT05473507
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Dermtech tape-stripping, Digital Dermoscopy, Optical coherence tomography (OCT), Reflectance confocal microscopy (RCM), Total Skin Examinations
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 16, 2026, 2:36 AM EDT
Active, not recruiting Not applicable Interventional

Research on Infarction With Open Arteries Using OCT and CMR

NCT02270359
View directory record Official record
Conditions
Myocardial Infarction
Interventions
CMR, OCT, contrast agent, Gadolinium
Procedure · Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 6, 2026, 8:13 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
CAM2029, Lanreotide ATG, Octreotide LAR
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Jul 28, 2026, 9:25 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

NCT04644575
View directory record Official record
Conditions
Hemophilia A
Interventions
efanesoctocog alfa (BIVV001)
Drug
Lead sponsor
Bioverativ, a Sanofi company
Industry
Eligibility
Not listed
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 14, 2026, 10:19 PM EDT
Active, not recruiting Not applicable Interventional

Intravascular Neuro OCT Imaging System for Aneurysm Treatment Evaluation

NCT07214220
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
Endovascular Intracranial aneurysm treatment, nOCT imaging
Procedure · Device
Lead sponsor
Spryte Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Jacksonville, Florida • Tampa, Florida • Park Ridge, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 13, 2026, 9:24 PM EDT
Active, not recruiting No phase listed Observational

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

NCT03932201
View directory record Official record
Conditions
Hemophilia A
Interventions
Damoctocog alfa pegol (Jivi, Bay94-9027)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Mobile, Alabama • Phoenix, Arizona • Davis, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 6:22 AM EDT
Active, not recruiting No phase listed Observational

Multicenter Phenotype-Genotype Analysis of Vascular Stains to Optimize Treatment Utilizing Optical Coherence Tomography

NCT04772911
View directory record Official record
Conditions
Vascular Stains
Interventions
Optical Coherence Tomography (OCT)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Irvine, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 16, 2026, 4:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Sleep Aging and Risk for Alzheimer's 2.0

NCT03278119
View directory record Official record
Conditions
Alzheimer Disease, Sleep Apnea
Interventions
PET Scan and nocturnal polysomnography
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 15, 2026, 12:43 PM EDT
Active, not recruiting No phase listed Observational

Heart Attack Research Program- Imaging Study

NCT02905357
View directory record Official record
Conditions
Myocardial Infarction
Interventions
CMR, OCT
Other · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 99 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 28, 2026, 11:02 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating Raised Intracranial Pressure Using MR Elastography

NCT03096743
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Lumbar puncture, MR elastography, MRI structural brain imaging, Optic nerve B-scan ultrasound, Optical Coherence Tomography (OCT) imaging
Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 29, 2026, 1:53 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)

NCT03963817
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
adaptive optics AO-OCT/AF instrument
Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
60 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 14, 2026, 3:03 PM EDT
Active, not recruiting No phase listed Observational

Evaluation of Symphony™ Posterior Cervical System for Surgical Treatment of Adult Cervical Deformity

NCT04912674
View directory record Official record
Conditions
Cervical Deformity
Interventions
Symphony OCT System
Device
Lead sponsor
International Spine Study Group Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Sacramento, California • Denver, Colorado • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 14, 2026, 12:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
2.5% Lys-Arg sterile amino acid solution, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), High dose 60 mg octreotide long-acting repeatable, Lutathera
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 14, 2026, 10:00 AM EDT
Active, not recruiting No phase listed Observational

Massachusetts General Hospital and Tsuchiura Kyodo General Hospital Coronary Imaging Collaboration

NCT04523194
View directory record Official record
Conditions
Atherosclerosis
Interventions
Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jul 30, 2026, 8:19 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb

NCT06300996
View directory record Official record
Conditions
SMA, Spinal Muscular Atrophy, Spinal Muscular Atrophy 4, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type II
Interventions
Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads)
Device
Lead sponsor
Marco Capogrosso
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Aug 16, 2026, 9:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy

NCT04737616
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause
Interventions
CO2 laser, OCT
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Jul 28, 2026, 1:29 PM EDT
Active, not recruiting Early Phase 1 Interventional

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

NCT03044977
View directory record Official record
Conditions
Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting, Neuroendocrine Tumor, Malignant
Interventions
131I-MIBG, 90Y-DOTA-3-Tyr-Octreotide
Drug
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Jul 28, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Graded Insulin Suppression Test P&F

NCT06592261
View directory record Official record
Conditions
Healthy, Hyperinsulinemia, Insulin Resistance, Obesity
Interventions
Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min, Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 8:17 PM EDT
Withdrawn Phase 1 Interventional

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

NCT06881888
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Octreotide (drug), Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 11:50 PM EDT